TRIPTODUR KIT (triptorelin pamoate)
TRIPTODUR KIT is indicated for the treatment of Prostate Cancer.
How TRIPTODUR KIT Works
Triptorelin is a synthetic decapeptide agonist analog of endogenous gonadotropin-releasing hormone (GnRH) with greater potency. Initially, triptorelin stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). However, chronic administration leads to the downregulation of pituitary GnRH receptors and desensitization of pituitary gonadotropes. This results in a sustained suppression of LH and FSH secretion, subsequently reducing serum concentrations of gonadal steroids (testosterone in males and estradiol in females) to prepubertal levels.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2017-06-29
- Patent Cliff
- 2029
- Routes
- INTRAMUSCULAR
- Dosage Forms
- FOR SUSPENSION, EXTENDED RELEASE
TRIPTODUR KIT Approval History
What TRIPTODUR KIT Treats
1 indicationsTRIPTODUR KIT is approved for 1 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Prostate Cancer
TRIPTODUR KIT Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in TRIPTODUR KIT's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications TRIPTODUR KIT treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to TRIPTODUR KIT
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
4 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06513962 | ALTE2131 NCI-2024-05414, ALTE2131 | Ph 3 | recruiting | Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer |
| NCT05029622 results posted | D-CN-52014-244 2022-003857-78 | Ph 3 | completed | A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty. |
| NCT02168062 results posted | 135513 NCI-2015-01058 | Ph 2 | terminated | Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer |
| NCT01161563 results posted | TRE1001 | Ph 4 | completed | Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TRIPTODUR KIT FDA Label Details
Indications & Usage
FDA Label (PDF)TRIPTODUR KIT is indicated for the treatment of Prostate Cancer.
TRIPTODUR KIT Patents & Exclusivity
Patents (1 active)
Pro Intelligence Preview
Deep insights for TRIPTODUR KIT
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2029
- • 1 active patents
Trial Analysis
- • 4 total trials
- • Stage: Stable
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment